These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 22107847)

  • 21. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy.
    Findlow J; Borrow R; Snape MD; Dawson T; Holland A; John TM; Evans A; Telford KL; Ypma E; Toneatto D; Oster P; Miller E; Pollard AJ
    Clin Infect Dis; 2010 Nov; 51(10):1127-37. PubMed ID: 20954968
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genomic Characterization of Invasive Meningococcal Serogroup B Isolates and Estimation of 4CMenB Vaccine Coverage in Finland.
    Bodini M; Brozzi A; Giuliani M; Nohynek H; Vainio A; Kuusi M; De Paola R; Pizza M; Medini D; Toropainen M; Serino L; Muzzi A
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence and sequence variations of the genes encoding the five antigens included in the novel 5CVMB vaccine covering group B meningococcal disease.
    Jacobsson S; Hedberg ST; Mölling P; Unemo M; Comanducci M; Rappuoli R; Olcén P
    Vaccine; 2009 Mar; 27(10):1579-84. PubMed ID: 19162117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distribution of Bexsero® Antigen Sequence Types (BASTs) in invasive meningococcal disease isolates: Implications for immunisation.
    Brehony C; Rodrigues CMC; Borrow R; Smith A; Cunney R; Moxon ER; Maiden MCJ
    Vaccine; 2016 Sep; 34(39):4690-4697. PubMed ID: 27521232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus.
    Bambini S; Muzzi A; Olcen P; Rappuoli R; Pizza M; Comanducci M
    Vaccine; 2009 May; 27(21):2794-803. PubMed ID: 19428890
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment.
    Vogel U; Taha MK; Vazquez JA; Findlow J; Claus H; Stefanelli P; Caugant DA; Kriz P; Abad R; Bambini S; Carannante A; Deghmane AE; Fazio C; Frosch M; Frosi G; Gilchrist S; Giuliani MM; Hong E; Ledroit M; Lovaglio PG; Lucidarme J; Musilek M; Muzzi A; Oksnes J; Rigat F; Orlandi L; Stella M; Thompson D; Pizza M; Rappuoli R; Serruto D; Comanducci M; Boccadifuoco G; Donnelly JJ; Medini D; Borrow R
    Lancet Infect Dis; 2013 May; 13(5):416-25. PubMed ID: 23414709
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic distribution of noncapsular meningococcal group B vaccine antigens in Neisseria lactamica.
    Lucidarme J; Gilchrist S; Newbold LS; Gray SJ; Kaczmarski EB; Richardson L; Bennett JS; Maiden MC; Findlow J; Borrow R
    Clin Vaccine Immunol; 2013 Sep; 20(9):1360-9. PubMed ID: 23803905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine.
    Medini D; Stella M; Wassil J
    Vaccine; 2015 May; 33(23):2629-36. PubMed ID: 25882169
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence and genetic characteristics of 4CMenB and rLP2086 vaccine candidates among Neisseria meningitidis serogroup B strains, China.
    Zhu B; Shi F; Zhang A; Sun X; Xu Z; Xu L; Gao Y; Lv J; Shao Z
    Vaccine; 2018 Apr; 36(15):1983-1989. PubMed ID: 29523451
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High coverage of diverse invasive meningococcal serogroup B strains by the 4-component vaccine 4CMenB in Australia, 2007-2011: Concordant predictions between MATS and genetic MATS.
    Tozer SJ; Smith HV; Whiley DM; Borrow R; Boccadifuoco G; Medini D; Serruto D; Giuliani MM; Stella M; De Paola R; Muzzi A; Pizza M; Sloots TP; Nissen MD
    Hum Vaccin Immunother; 2021 Sep; 17(9):3230-3238. PubMed ID: 33847225
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Distribution of factor H binding protein beyond serogroup B: variation among five serogroups of invasive Neisseria meningitidis in South Africa.
    Mothibeli KM; du Plessis M; von Gottberg A; Murphy E; Hoiseth SK; Zlotnick G; Klugman KP
    Vaccine; 2011 Mar; 29(11):2187-92. PubMed ID: 21144918
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Development of a Vaccine Against Meningococcus B Using Reverse Vaccinology.
    Masignani V; Pizza M; Moxon ER
    Front Immunol; 2019; 10():751. PubMed ID: 31040844
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Meningococcal Antigen Typing System (MATS): A Tool to Estimate Global Coverage for 4CMenB, a Multicomponent Meningococcal B Vaccine.
    Boccadifuoco G; Brunelli B; Mori E; Agnusdei M; Gianfaldoni C; Giuliani MM
    Methods Mol Biol; 2019; 1969():205-215. PubMed ID: 30877679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential benefits of using a multicomponent vaccine for prevention of serogroup B meningococcal disease.
    Watson PS; Novy PL; Friedland LR
    Int J Infect Dis; 2019 Aug; 85():22-27. PubMed ID: 31102824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of vaccine antigen characterization, for example by MATS, to guide the introduction of meningococcus B vaccines.
    Vogel U; Stefanelli P; Vazquez J; Taha MK; Claus H; Donnelly J
    Vaccine; 2012 May; 30 Suppl 2():B73-7. PubMed ID: 22607902
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sequence variation in the porB gene from B:P1.4 meningococci causing New Zealand's epidemic.
    Dyet KH; Martin DR
    J Clin Microbiol; 2005 Feb; 43(2):838-42. PubMed ID: 15695689
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic Meningococcal Antigen Typing System (gMATS): A genotyping tool that predicts 4CMenB strain coverage worldwide.
    Muzzi A; Brozzi A; Serino L; Bodini M; Abad R; Caugant D; Comanducci M; Lemos AP; Gorla MC; Křížová P; Mikula C; Mulhall R; Nissen M; Nohynek H; Simões MJ; Skoczyńska A; Stefanelli P; Taha MK; Toropainen M; Tzanakaki G; Vadivelu-Pechai K; Watson P; Vazquez JA; Rajam G; Rappuoli R; Borrow R; Medini D
    Vaccine; 2019 Feb; 37(7):991-1000. PubMed ID: 30661831
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transcriptional regulation of the nadA gene in Neisseria meningitidis impacts the prediction of coverage of a multicomponent meningococcal serogroup B vaccine.
    Fagnocchi L; Biolchi A; Ferlicca F; Boccadifuoco G; Brunelli B; Brier S; Norais N; Chiarot E; Bensi G; Kroll JS; Pizza M; Donnelly J; Giuliani MM; Delany I
    Infect Immun; 2013 Feb; 81(2):560-9. PubMed ID: 23230289
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans.
    Toneatto D; Ismaili S; Ypma E; Vienken K; Oster P; Dull P
    Hum Vaccin; 2011 Jun; 7(6):646-53. PubMed ID: 21904120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of factor H Binding Protein sub-variants among Neisseria meningitidis in China.
    Shi F; Zhang A; Zhu B; Gao Y; Xu L; Li Y; Yin Z; Li J; Xie N; Shao Z
    Vaccine; 2017 Apr; 35(18):2343-2350. PubMed ID: 28351732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.